Doxorubicin Anthracycline Antibiotic Broad Spectrum Chemotherapeutic Agent Biology essay
Doxorubicin is an antibiotic derived from the Streptomyces peucetius bacteria. It has been used since s. Doxorubicin is part of the anthracycline group. This review aims to gather information on the anticancer mechanisms of DOX and its influence on the antitumor immune response, providing a rationale. Doxorubicin is one of the cytotoxic anthracycline agents derived from Streptomyces spp. The anthracycline class of agents has been used over the past thirty years as a treatment against a number of anthracyclines, most notably Doxorubicin DOX. The rhodomycins were the first anthracycline compounds, identified by Brockmann and Bauer, originally studied as potential antibiotics, and found effective versus; Doxorubicin or Adriamycin is a versatile drug with multiple intracellular targets at low concentrations and can enhance the immunogenicity of infected cells. Doxorubicin DOX is an anthracycline antibiotic isolated from Streptomyces peucetius and is widely used as an antineoplastic agent. That is to say, Doxorubicin is a commonly used anti-cancer drug that causes DNA damage. However, its use is limited by its dose-dependent side effects, such as cardiac toxicity. Cholesterol-lowering statin. Doxorubicin Dox is an anthracycline antibiotic with a broad spectrum of chemotherapeutic competence. 5, 6 Although chemotherapy is well established, we mainly focus on the applications of Alg as a carrier for a chemotherapeutic agent, Doxorubicin DOX, also called Adriamycin. It is a broad-spectrum antitumor antibiotic isolated from Streptomyces species. In the cancer cell, DOX intercalates into DNA and disrupts topoisomerase II-mediated DNA repair. Doxorubicin DOX is an anthracycline antibiotic widely used as a chemotherapeutic agent to treat solid tumors and hematological malignancies. Although useful in the treatment of cancer, the benefit of DOX is limited due to the cardiotoxic effect seen in a large number of patients. In th, Doxorubicin DOX, a commonly used drug in cancer chemotherapy, induces cell death via multiple intracellular interactions, generating reactive oxygen species and DNA-adducted configurations. Doxorubicin DOX, Adriamycin is a cytotoxic anthracycline antibiotic. It has since been widely used as a chemotherapeutic agent for the treatment of a variety of cancers such as breast cancer, ovarian cancer, lymphoma, leukemia, etc. Doxorubicin may cause ovarian toxicity, including decreased ovarian hormone secretion. Anthracyclines are effective and potent agents with a broad antitumor spectrum, but can cause side effects including hair loss, myelotoxicity and cardiotoxicity. We used hematopoietic stimulating factors to control myelotoxicity, such as G-CSF, EPO and TPO. However, cardiotoxicity is the most serious side effect of. Dexrazoxane is the only FDA-approved cardioprotective agent for anthracycline-induced cardiotoxicity.31 Dexrazoxane is an adjunctive agent that may act as a free radical scavenger. It is converted into a ring-opening chelating agent and can replace, complex and combine with iron in doxorubicin. Chemotherapeutic agents for the treatment of breast cancer, such as anthracyclines, epipodophyllotoxins, anthracenedione and aminoacridone, inhibit the enzyme topoisomerase IIα 25 26 27 The fluorescence excitation spectra were measured nm observation and fluorescence emission spectra were excited nm.,